• S. Bernard (SafeMinds), 2003. Analysis and Critique of the CDC’s Handling of the Thimerosal Exposure Assessment Based on Vaccine Safety Datalink (VSD) information.

  • S. Bernard (SafeMinds), 2004. “VSD Thimerosal Analysis of June 2000” Background Information on this Document by SafeMinds.

  • Teresa Binstock (researcher), 2004. Increased susceptibility to adverse effects from vaccinations.

  • M. Blaxill, L. Redwood, S. Bernard (submitted by: SafeMinds). Thimerosal and Autism? A plausible hypothesis that should not be dismissed. A response to: K.B. Nelson and M.L. Bauman. (2003) Thimerosal and Autism? Pediatrics 111(3):674-9.

  • J. Bradstreet, 2004. Biological Evidence of Significant Vaccine Related Side-effects Resulting in Neurodevelopmental Disorders.

  • J. Bradstreet. 2004. Is There a Nexus for MMR and Mercury Issues in Autism Spectrum Disorders.

  • R. Deth, 2004. Molecular Basis of the Link Between Thimerosal and Autism.

  • M. Geier and D. Geier, 2004. From Epidemiology, Clinical Medicine, Molecular Biology, and Atoms, to Politics: A Review of the Relationship between Thimerosal and Autism.

  • E.H. Granai, 2004. Are Some Cases of Autism the Result of a Persistent, Attenuated Rubella Infection in the Mother?

  • E.H. Granai, 2004. The Phenomenon of a Concentration of Autistic Children’s Births in the Months of March and August.

  • B. Haley, 2004. Biomedical Aspects of Thimerosal Exposure.

  • S.J. James, 2004. Impaired transsulfuration and oxidative stress in autistic children: Improvement with targeted nutritional intervention (submitted by J. Bradstreet).

  • V. Singh, 2004. Autism, Vaccines, and Immune Reactions.

4) TRANSCRIPTS AND CONGRESSIONAL RECORDS

  • Congressional Record—Extension of Remarks. May 20, 3003. Mercury in Medicine Report. Hon. Dan Burton of Indiana, In the House of Representatives (submitted by Mark and David Geier).

  • Dan Burton. May 2003. Mercury in Medicine; Taking Unnecessary Risks. (A report Prepared by the Staff of the Subcommittee on Human Rights and Wellness, Committee on Government Reform, United States House of Representatives) (submitted by Mark and David Geier).

  • Dan Burton (Chairman): Opening statement; “FACA: Conflicts of Interest and Vaccine Development: Preserving the Integrity of the Process. June 15, 2000. Washington, DC. (submitted by R. Gallup, The Autism Autoimmunity Project).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement